 CAMBRIDGE, Mass. , Sept. 26, 2022 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic ProgrammingTM platform, today announced that members of management will participate in two upcoming investor conferences. 